Biosimilars Now Look Like a Surer Thing After Initial Skepticism
The Inflation Reduction Act boosted the Medicare payment for biosimilars from the standard average sales price plus 6% to 8%.
Inflation Reduction Act to Allow "Smoothing" of Medicare Part D Out of Pocket Costs
Gottlieb on creating space for opportunity and innovation
At the 2019 Asembia Specialty Pharmacy Summit, former FDA Commissioner Scott Gottlieb discussed advances within the agency during his tenure.